PURPOSE: To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures. PATIENTS AND METHODS: Younger (< 60 years; n = 175) and older (≥ 60 years; n = 225) patients with CN-AML treated with intensive cytarabine/anthracycline-based first-line therapy on Cancer and Leukemia Group B protocols were centrally analyzed for RUNX1 mutations by polymerase chain reaction and direct sequencing and for established prognostic gene mutations. Gene/microRNA expression profiles were derived using microarrays. RESULTS: RUNX1 mutations were found in 8% and 16% of younger and older patients, respectively (P = .02). They were associated with ASXL1 mutations (P < .001) and inversely associated with NPM1 (P < .001) and CEBPA (P = .06) mutations. RUNX1-mutated patients had lower complete remission rates (P = .005 in younger; P = .006 in older) and shorter disease-free survival (P = .058 in younger; P < .001 in older), overall survival (P = .003 in younger; P < .001 in older), and event-free survival (P < .001 for younger and older) than RUNX1 wild-type patients. Because RUNX1 mutations were more common in older patients and almost never coexisted with NPM1 mutations, RUNX1 mutation-associated expression signatures were derived in older, NPM1 wild-type patients and featured upregulation of genes normally expressed in primitive hematopoietic cells and B-cell progenitors, including DNTT, BAALC, BLNK, CD109, RBPMS, and FLT3, and downregulation of promoters of myelopoiesis, including CEBPA and miR-223. CONCLUSION: RUNX1 mutations are twice as common in older than younger patients with CN-AML and negatively impact outcome in both age groups. RUNX1-mutated blasts have molecular features of primitive hematopoietic and lymphoid progenitors, potentially leading to novel therapeutic approaches.
PURPOSE: To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures. PATIENTS AND METHODS: Younger (< 60 years; n = 175) and older (≥ 60 years; n = 225) patients with CN-AML treated with intensive cytarabine/anthracycline-based first-line therapy on Cancer and Leukemia Group B protocols were centrally analyzed for RUNX1 mutations by polymerase chain reaction and direct sequencing and for established prognostic gene mutations. Gene/microRNA expression profiles were derived using microarrays. RESULTS:RUNX1 mutations were found in 8% and 16% of younger and older patients, respectively (P = .02). They were associated with ASXL1 mutations (P < .001) and inversely associated with NPM1 (P < .001) and CEBPA (P = .06) mutations. RUNX1-mutated patients had lower complete remission rates (P = .005 in younger; P = .006 in older) and shorter disease-free survival (P = .058 in younger; P < .001 in older), overall survival (P = .003 in younger; P < .001 in older), and event-free survival (P < .001 for younger and older) than RUNX1 wild-type patients. Because RUNX1 mutations were more common in older patients and almost never coexisted with NPM1 mutations, RUNX1 mutation-associated expression signatures were derived in older, NPM1 wild-type patients and featured upregulation of genes normally expressed in primitive hematopoietic cells and B-cell progenitors, including DNTT, BAALC, BLNK, CD109, RBPMS, and FLT3, and downregulation of promoters of myelopoiesis, including CEBPA and miR-223. CONCLUSION:RUNX1 mutations are twice as common in older than younger patients with CN-AML and negatively impact outcome in both age groups. RUNX1-mutated blasts have molecular features of primitive hematopoietic and lymphoid progenitors, potentially leading to novel therapeutic approaches.
Authors: Klaus H Metzeler; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Heiko Becker; John Curfman; Kelsi B Holland; Sebastian Schwind; Susan P Whitman; Yue-Zhong Wu; William Blum; Bayard L Powell; Thomas H Carter; Meir Wetzler; Joseph O Moore; Jonathan E Kolitz; Maria R Baer; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield Journal: J Clin Oncol Date: 2011-02-22 Impact factor: 44.544
Authors: Klaus H Metzeler; Heiko Becker; Kati Maharry; Michael D Radmacher; Jessica Kohlschmidt; Krzysztof Mrózek; Deedra Nicolet; Susan P Whitman; Yue-Zhong Wu; Sebastian Schwind; Bayard L Powell; Thomas H Carter; Meir Wetzler; Joseph O Moore; Jonathan E Kolitz; Maria R Baer; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield Journal: Blood Date: 2011-10-26 Impact factor: 22.113
Authors: Guido Marcucci; Klaus H Metzeler; Sebastian Schwind; Heiko Becker; Kati Maharry; Krzysztof Mrózek; Michael D Radmacher; Jessica Kohlschmidt; Deedra Nicolet; Susan P Whitman; Yue-Zhong Wu; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Joseph O Moore; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield Journal: J Clin Oncol Date: 2012-01-30 Impact factor: 44.544
Authors: Kolja Eppert; Katsuto Takenaka; Eric R Lechman; Levi Waldron; Björn Nilsson; Peter van Galen; Klaus H Metzeler; Armando Poeppl; Vicki Ling; Joseph Beyene; Angelo J Canty; Jayne S Danska; Stefan K Bohlander; Christian Buske; Mark D Minden; Todd R Golub; Igor Jurisica; Benjamin L Ebert; John E Dick Journal: Nat Med Date: 2011-08-28 Impact factor: 53.440
Authors: Guido Marcucci; Kati Maharry; Yue-Zhong Wu; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Kelsi B Holland; Susan P Whitman; Heiko Becker; Sebastian Schwind; Klaus H Metzeler; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield Journal: J Clin Oncol Date: 2010-04-05 Impact factor: 50.717
Authors: Verena I Gaidzik; Lars Bullinger; Richard F Schlenk; Andreas S Zimmermann; Jürgen Röck; Peter Paschka; Andrea Corbacioglu; Jürgen Krauter; Brigitte Schlegelberger; Arnold Ganser; Daniela Späth; Andrea Kündgen; Ingo G H Schmidt-Wolf; Katharina Götze; David Nachbaur; Michael Pfreundschuh; Heinz A Horst; Hartmut Döhner; Konstanze Döhner Journal: J Clin Oncol Date: 2011-02-22 Impact factor: 50.717
Authors: Deli Hong; Andrew J Fritz; Jonathan A Gordon; Coralee E Tye; Joseph R Boyd; Kirsten M Tracy; Seth E Frietze; Frances E Carr; Jeffrey A Nickerson; Andre J Van Wijnen; Anthony N Imbalzano; Sayyed K Zaidi; Jane B Lian; Janet L Stein; Gary S Stein Journal: J Cell Physiol Date: 2018-12-04 Impact factor: 6.384
Authors: D M Ross; H K Altamura; C N Hahn; M Nicola; A L Yeoman; M R Holloway; J Geoghegan; J Feng; A W Schreiber; S Branford; S Moore; H S Scott Journal: Leukemia Date: 2015-10-27 Impact factor: 11.528
Authors: Stephen A Strickland; Aaron C Shaver; Michael Byrne; Robert D Daber; P Brent Ferrell; David R Head; Sanjay R Mohan; Claudio A Mosse; Tamara K Moyo; Thomas P Stricker; Cindy Vnencak-Jones; Michael R Savona; Adam C Seegmiller Journal: Leuk Res Date: 2018-01-02 Impact factor: 3.156
Authors: Shan Lin; Anetta Ptasinska; Xiaoting Chen; Mahesh Shrestha; Salam A Assi; Paulynn S Chin; Maria R Imperato; B J Aronow; Jingsong Zhang; Matthew T Weirauch; Constanze Bonifer; James C Mulloy Journal: Blood Date: 2017-07-14 Impact factor: 22.113
Authors: Jason H Mendler; Kati Maharry; Heiko Becker; Ann-Kathrin Eisfeld; Leigha Senter; Krzysztof Mrózek; Jessica Kohlschmidt; Klaus H Metzeler; Sebastian Schwind; Susan P Whitman; Jihane Khalife; Michael A Caligiuri; Rebecca B Klisovic; Joseph O Moore; Thomas H Carter; Guido Marcucci; Clara D Bloomfield Journal: Haematologica Date: 2013-06-10 Impact factor: 9.941
Authors: Guido Marcucci; Kati S Maharry; Klaus H Metzeler; Stefano Volinia; Yue-Zhong Wu; Krzysztof Mrózek; Deedra Nicolet; Jessica Kohlschmidt; Susan P Whitman; Jason H Mendler; Sebastian Schwind; Heiko Becker; Ann-Kathrin Eisfeld; Andrew J Carroll; Bayard L Powell; Jonathan E Kolitz; Ramiro Garzon; Michael A Caligiuri; Richard M Stone; Clara D Bloomfield Journal: J Clin Oncol Date: 2013-05-06 Impact factor: 44.544